ATE466081T1 - Zusammensetzungen und verfahren zur regulierung eines komplementsystems - Google Patents

Zusammensetzungen und verfahren zur regulierung eines komplementsystems

Info

Publication number
ATE466081T1
ATE466081T1 AT06850425T AT06850425T ATE466081T1 AT E466081 T1 ATE466081 T1 AT E466081T1 AT 06850425 T AT06850425 T AT 06850425T AT 06850425 T AT06850425 T AT 06850425T AT E466081 T1 ATE466081 T1 AT E466081T1
Authority
AT
Austria
Prior art keywords
complement pathway
compositions
regulating
methods
complement system
Prior art date
Application number
AT06850425T
Other languages
English (en)
Inventor
Samuel Jotham Reich
Nadine Dejneka
Original Assignee
Opko Ophthalmics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Ophthalmics Llc filed Critical Opko Ophthalmics Llc
Application granted granted Critical
Publication of ATE466081T1 publication Critical patent/ATE466081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
AT06850425T 2005-12-22 2006-12-22 Zusammensetzungen und verfahren zur regulierung eines komplementsystems ATE466081T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75304105P 2005-12-22 2005-12-22
PCT/US2006/062568 WO2007089375A2 (en) 2005-12-22 2006-12-22 Compositions and methods for regulating complement system

Publications (1)

Publication Number Publication Date
ATE466081T1 true ATE466081T1 (de) 2010-05-15

Family

ID=38234879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850425T ATE466081T1 (de) 2005-12-22 2006-12-22 Zusammensetzungen und verfahren zur regulierung eines komplementsystems

Country Status (11)

Country Link
US (1) US20070178068A1 (de)
EP (2) EP2221378B1 (de)
JP (1) JP2009521234A (de)
AT (1) ATE466081T1 (de)
AU (1) AU2006337093B2 (de)
CA (1) CA2634286A1 (de)
DE (1) DE602006014026D1 (de)
IL (2) IL192282A (de)
MX (1) MX2008008302A (de)
NZ (1) NZ569368A (de)
WO (1) WO2007089375A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495121A2 (de) 2002-04-18 2005-01-12 Lynkeus Biotech GmbH Mitteln und verfahren zur spezifischen hemmung von genen in zellen und gewebe vom zns und/oder dem auge
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2007095154A2 (en) * 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
WO2007146953A2 (en) * 2006-06-12 2007-12-21 Exegenics, Inc., D/B/A Opko Health, Inc. Compositions and methods for sirna inhibition of angiogenesis
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US8580735B2 (en) * 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US8940299B2 (en) * 2008-02-28 2015-01-27 Case Western Reserve University Method of treating cancer
CN102149390A (zh) * 2008-07-10 2011-08-10 阿姆斯特丹大学附属医院 补体拮抗剂及其应用
WO2010042530A2 (en) * 2008-10-06 2010-04-15 Baylor College Of Medicine Nlrc5 as a target for immune therapy
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
EP2756845B1 (de) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
CA3107872A1 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
EP3177732A4 (de) * 2014-08-08 2018-04-25 ModernaTX, Inc. Zusammensetzungen und verfahren zur behandlung von augenerkrankungen und augenleiden
EP3229586A4 (de) * 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetisch modifizierte zellen, gewebe und organe zur behandlung von krankheiten
CN108934169A (zh) 2016-01-20 2018-12-04 维特里萨医疗公司 用于抑制因子d的组合物和方法
JP2020500157A (ja) 2016-10-17 2020-01-09 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｃ３阻害のための組み合わせ治療
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2019089922A1 (en) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2020086735A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
KR20220084399A (ko) * 2019-10-22 2022-06-21 알닐람 파마슈티칼스 인코포레이티드 보체 성분 C3 iRNA 조성물 및 이의 사용 방법
WO2023031359A1 (en) 2021-09-02 2023-03-09 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023186056A1 (zh) * 2022-04-02 2023-10-05 上海舶望制药有限公司 用于抑制补体成分c3蛋白表达的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US20030096775A1 (en) * 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
EP2028278B1 (de) 2000-03-30 2014-03-19 Whitehead Institute For Biomedical Research RNA-sequenzspezifische Mediatoren von RNA-Interferenz
DK2813582T3 (en) * 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US7816497B2 (en) * 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
ES2440284T3 (es) * 2002-11-14 2014-01-28 Thermo Fisher Scientific Biosciences Inc. ARNip dirigido a tp53
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
CA2670801A1 (en) * 2005-11-30 2007-06-07 Intradigm Corporation Compositions and methods of using sirna to knockdown gene expression and to improve solid organ and cell transplantation

Also Published As

Publication number Publication date
IL192282A (en) 2012-12-31
DE602006014026D1 (de) 2010-06-10
WO2007089375A2 (en) 2007-08-09
WO2007089375A3 (en) 2007-12-06
IL223632A0 (en) 2013-02-03
EP1966379A2 (de) 2008-09-10
CA2634286A1 (en) 2007-08-09
EP2221378A1 (de) 2010-08-25
AU2006337093A1 (en) 2007-08-09
MX2008008302A (es) 2009-01-21
JP2009521234A (ja) 2009-06-04
US20070178068A1 (en) 2007-08-02
EP2221378B1 (de) 2013-04-17
EP1966379B1 (de) 2010-04-28
AU2006337093B2 (en) 2013-03-14
NZ569368A (en) 2011-11-25
IL192282A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
ATE466081T1 (de) Zusammensetzungen und verfahren zur regulierung eines komplementsystems
BRPI0519508A2 (pt) análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase
DE502005011119D1 (de)
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
ATE477337T1 (de) Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2007109097A3 (en) RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
MX2010006422A (es) Proteinas de union a antigenos.
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
EA201790267A1 (ru) Новые модуляторы киназ
DE602005008970D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
MX2012004638A (es) Modulacion de degeneracion de axones.
ATE460500T1 (de) Zusammensetzungen und verfahren zur sirna- inhibition der angiogenese
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
WO2008110885A3 (en) Methods of treating ophthalmic diseases
AR036401A1 (es) Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
ATE485047T1 (de) Verwendung eines wachstumsstimulierenden proteins
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE602006002371D1 (de) Verfahren zur herstellung von brillengläsern
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
CO2023000016A2 (es) Proteínas enpp1 o enpp3 solubles y sus usos
DOP2007000020A (es) Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties